These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 16088978)

  • 1. AKT activation predicts outcome in breast cancer patients treated with tamoxifen.
    Kirkegaard T; Witton CJ; McGlynn LM; Tovey SM; Dunne B; Lyon A; Bartlett JM
    J Pathol; 2005 Oct; 207(2):139-46. PubMed ID: 16088978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bad expression predicts outcome in patients treated with tamoxifen.
    Cannings E; Kirkegaard T; Tovey SM; Dunne B; Cooke TG; Bartlett JM
    Breast Cancer Res Treat; 2007 Apr; 102(2):173-9. PubMed ID: 17004114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Akt kinases in breast cancer and the results of adjuvant therapy.
    Stål O; Pérez-Tenorio G; Akerberg L; Olsson B; Nordenskjöld B; Skoog L; Rutqvist LE
    Breast Cancer Res; 2003; 5(2):R37-44. PubMed ID: 12631397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients.
    Pérez-Tenorio G; Stål O;
    Br J Cancer; 2002 Feb; 86(4):540-5. PubMed ID: 11870534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
    Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
    Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.
    Campbell RA; Bhat-Nakshatri P; Patel NM; Constantinidou D; Ali S; Nakshatri H
    J Biol Chem; 2001 Mar; 276(13):9817-24. PubMed ID: 11139588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K.
    Sun M; Paciga JE; Feldman RI; Yuan Z; Coppola D; Lu YY; Shelley SA; Nicosia SV; Cheng JQ
    Cancer Res; 2001 Aug; 61(16):5985-91. PubMed ID: 11507039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit.
    Bostner J; Karlsson E; Pandiyan MJ; Westman H; Skoog L; Fornander T; Nordenskjöld B; Stål O
    Breast Cancer Res Treat; 2013 Jan; 137(2):397-406. PubMed ID: 23242584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R6. PubMed ID: 24447434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications.
    Badve S; Collins NR; Bhat-Nakshatri P; Turbin D; Leung S; Thorat M; Dunn SE; Geistlinger TR; Carroll JS; Brown M; Bose S; Teitell MA; Nakshatri H
    Am J Pathol; 2010 May; 176(5):2139-49. PubMed ID: 20228224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
    Jordan NJ; Gee JM; Barrow D; Wakeling AE; Nicholson RI
    Breast Cancer Res Treat; 2004 Sep; 87(2):167-80. PubMed ID: 15377841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?
    Tovey S; Dunne B; Witton CJ; Forsyth A; Cooke TG; Bartlett JM
    Clin Cancer Res; 2005 Jul; 11(13):4835-42. PubMed ID: 16000581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTEN protein expression in postmenopausal steroid receptor positive early breast cancer patients treated with adjuvant tamoxifen.
    Milovanovic Z; Dzodic R; Susnjar S; Plesinac-Karapandzic V; Juranic Z; Tatic S
    J BUON; 2011; 16(1):46-51. PubMed ID: 21674849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of PI3K/Akt signaling and hormone resistance in breast cancer.
    Tokunaga E; Kimura Y; Mashino K; Oki E; Kataoka A; Ohno S; Morita M; Kakeji Y; Baba H; Maehara Y
    Breast Cancer; 2006; 13(2):137-44. PubMed ID: 16755107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high AR:ERα or PDEF:ERα ratio predicts a sub-optimal response to tamoxifen therapy in ERα-positive breast cancer.
    Cao L; Xiang G; Liu F; Xu C; Liu J; Meng Q; Lyu S; Wang S; Niu Y
    Cancer Chemother Pharmacol; 2019 Sep; 84(3):609-620. PubMed ID: 31297554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS; Kim SW
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients.
    Tokunaga E; Kimura Y; Oki E; Ueda N; Futatsugi M; Mashino K; Yamamoto M; Ikebe M; Kakeji Y; Baba H; Maehara Y
    Int J Cancer; 2006 Jan; 118(2):284-9. PubMed ID: 16049961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
    Vilquin P; Villedieu M; Grisard E; Ben Larbi S; Ghayad SE; Heudel PE; Bachelot T; Corbo L; Treilleux I; Vendrell JA; Cohen PA
    Int J Cancer; 2013 Oct; 133(7):1589-602. PubMed ID: 23553037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.